BrightHeart Garners Third FDA Clearance for AI-Powered Assessments of Fetal Heart Ultrasound
The latest FDA 510(k) clearance is for B-Right Views, an AI-enabled device, which provides automated detection of required views necessary for second- and third-trimester fetal heart ultrasound exams.
The Food and Drug Administration (FDA) has granted 510(k) clearance for B-Right Views, a device that utilizes artificial intelligence (AI) to help ensure standard fetal heart ultrasound views during second- and third-trimester exams.
By providing automated confirmation when recommended views are obtained and documented for the second- and third-trimester ultrasound exams, B-Right Views facilitates a consistent level of fetal heart ultrasound assessment for clinicians regardless of one’s ultrasound experience, according to BrightHeart, the developer of B-Right Views.
The newly FDA-cleared B-Right Views device utilizes artificial intelligence (AI) to provide automated confirmation when recommended views are obtained and documented for second- and third-trimester fetal heart ultrasound exams. (Image courtesy of BrightHeart.)
BrightHeart noted that the FDA clearance follows prior clearances for the company’s B-Right Screen AI software for detecting congenital heart defects and expanded clearance of that software earlier this month for accessing the AI feedback through a cart-side tablet.
The company added that it has also received approval for a Predetermined Change Control Plan (PCCP), which allows BrightHeart to make pre-authorized improvements to the AI device without the need for separate submissions for FDA clearance.
“BrightHeart’s AI has the potential to offer immediate workflow benefits and measurable clinical value,” said Nathan Fox, M.D., a clinical professor in the Raquel and Jaime Gilinski Department of Obstetrics, Gynecology, and Reproductive Science at the Icahn School of Medicine at Mount Sinai. “By providing real-time alerts, BrightHeart helps sonographers to identify and correct missing views during the exam, reducing the need for repeat scans while potentially boosting sonographer confidence and facilitating earlier triage of high-risk cases.”
Possible Real-Time Adaptive Approach to Breast MRI Suggests ‘New Era’ of AI-Directed MRI
June 3rd 2025Assessing the simulated use of AI-generated suspicion scores for determining whether one should continue with full MRI or shift to an abbreviated MRI, the authors of a new study noted comparable sensitivity, specificity, and positive predictive value for biopsies between the MRI approaches.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
